文献速递肝病

原发性硬化性胆管炎试验中血清碱性磷酸酶的个体间与个体内变异及有限的预后效用

Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-07-22

基于234例大胆管型原发性硬化性胆管炎患者参与的为期2年2b期安慰剂对照simtuzumab试验数据,分析血清碱性磷酸酶(ALP)和增强肝纤维化(ELF)评分随时间变化的个体间与个体内变异及其与纤维化进展的关联。结果显示ALP个体内变异大且与2年疾病进展无关,而ELF评分变异较小且多个时间点与纤维化进展和肝硬化发生相关。

要点

  • ALP在12、48、96周的中位个体内变异分别约为12%、20%、20%。
  • 基线ALP>2倍ULN者中1年ALP下降>40%占10.9%,2年占15.8%。
  • ELF评分12、48、96周的中位个体内变异分别约为3%、4%、4%。

核心结论

  • 大胆管型PSC患者血清ALP活性个体间和个体内变异大,且2年内与疾病进展无关;ELF评分变异较小,多个时间点与纤维化进展和肝硬化发生相关。

研究设计与样本

  • 分析234例大胆管型PSC患者的数据,患者来自一项为期2年、2b期安慰剂对照simtuzumab试验;每4周进行实验室检测,筛查时、第48周和第96周收集肝活检。

主要发现

  • simtuzumab组与安慰剂组血清ALP水平和ELF评分无显著差异,故数据合并分析。
  • ALP在12、48、96周的中位个体内变异分别约为12%、20%、20%;ELF评分分别约为3%、4%、4%。
  • 基线ALP>2倍ULN者中1年ALP下降>40%占10.9%,2年占15.8%;基线ALP>3倍ULN者中1年占12.5%,2年占17.9%。
  • 基线Ishak纤维化分期0-4期的209例患者中,血清ALP活性与2年时肝硬化发生或纤维化分期增加2分无关。
  • 基线及第12、24、48周ELF评分升高均与2年时肝硬化发生相关(比值比>2.75;所有时间点P<.01),也与2年时纤维化分期增加2分相关(所有时间点比值比均>2;P<.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Serum alkaline phosphatase (ALP) and the enhanced liver fibrosis (ELF) score are used as endpoints in trials of patients with primary sclerosing cholangitis (PSC). We aimed to quantify inter- and intra-individual variation in levels of ALP and the ELF score over time, and evaluated their association with fibrosis progression. METHODS: We analyzed data from 234 patients with large-duct PSC enrolled in a 2-year, phase 2b placebo-controlled trial of simtuzumab. Participants were assessed by laboratory tests every 4 weeks, and liver biopsies collected at time of screening, week 48, and week 96. RESULTS: Serum levels of ALP and ELF scores did not differ significantly between simtuzumab and placebo groups, so the data were pooled. Median per-patient variations in ALP between clinic visits were approximately 12% over 12 weeks, 20% over 48 weeks, and 20% over 96 weeks. Reductions, unrelated to study intervention, of more than 40% in ALP were observed in 10.9% of patients with baseline activity greater than 2-fold the upper limit of normal (ULN) and 12.5% of patients with more than 3-fold the ULN at 1 year. At 2 years, reductions of more than 40% in ALP were observed in 15.8% of patients with baseline activity greater than 2-fold the ULN and 17.9% of patients with more than 3-fold the ULN. Among the 209 patients with Ishak fibrosis stage 0-4 at baseline, serum ALP activity did not associate with development of cirrhosis or with a 2-point increase in fibrosis stage at 2 years. In contrast, the median per-patient variation in ELF scores between clinic visits was approximately 3% over 12 weeks, 4% over 48 weeks, and 4% over 96 weeks. Elevated ELF scores at baseline and at weeks 12, 24 and 48, each associated with development of cirrhosis at 2 years (odds ratio >2.75; P < .01 for all timepoints). ELF scores at baseline and weeks 12, 24 and 48, also associated with a 2-point increase in fibrosis stage at 2 years (odds ratios all greater than 2; P < .01 for all timepoints). CONCLUSIONS: In an analysis of data from patients with large-duct PSC enrolled in a prospective trial, we found large interindividual and intraindividual variations in serum ALP activity. Serum ALP activity did not associate with disease progression over a 2-year period. Variations in ELF score were smaller, and scores determined at multiple timepoints associated with fibrosis progression and development of cirrhosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Trivedi PJ, Muir AJ, Levy C, et al. Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2020. PMID: 32707342. doi:10.1016/j.cgh.2020.07.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。